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Abstract
Background: It is expected that increased demands on services will result from expanding numbers of older
people with long-term conditions and social care needs. There is significant interest in the potential for technology
to reduce utilisation of health services in these patient populations, including telecare (the remote, automatic and
passive monitoring of changes in an individual’s condition or lifestyle) and telehealth (the remote exchange of data
between a patient and health care professional). The potential of telehealth and telecare technology to improve
care and reduce costs is limited by a lack of rigorous evidence of actual impact.
Methods/Design: We are conducting a large scale, multi-site study of the implementation, impact and
acceptability of these new technologies. A major part of the evaluation is a cluster-randomised controlled trial of
telehealth and telecare versus usual care in patients with long-term conditions or social care needs. The trial
involves a number of outcomes, including health care utilisation and quality of life. We describe the broad
evaluation and the methods of the cluster randomised trial
Discussion: If telehealth and telecare technology proves effective, it will provide additional options for health
services worldwide to deliver care for populations with high levels of need.
Trial Registration: Current Controlled Trials ISRCTN43002091
Background
It is expected that increased demands on health and
social care services will result from the rise in the num-
bers of older people with long-term conditions and
social care needs [1]. While there are alternative propo-
sals about the implications of increasing numbers of
older people on demand for services [2], much planning
is predicated on expected increases in social and health
service use amongst older people. Shifting the balance
of care towards the home environment is seen as requir-
ing an investment in ‘upstream’ interventions by provid-
ing enhanced primary and community care-based
alternatives to secondary care and focusing on self-care
at the patient level.
The role of technology
In the current context of economic pressures and a
desire to secure efficiency savings, there is significant
interest in the potential for technology to reduce utilisa-
tion of health services in older people with long-term
conditions and social care needs, while improving the
quality and cost-effectiveness of care. There are a num-
ber of relevant types of telemonitoring technology and a
lack of consensus concerning terminology. For the pre-
sent paper we make the following distinction:
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• Telecare is the remote, automatic and passive
monitoring of changes in an individual’s condition
or lifestyle (including emergencies) in order to man-
age the risks of independent living. Examples include
movement sensors, falls sensors, and bed/chair occu-
pancy sensors. These technologies are generally pro-
vided to patients with social care needs.
• Telehealth is the remote exchange of data between
a patient and health care professional to assist in the
diagnosis and management of a health care condi-
tion. Examples include blood pressure and blood
glucose monitoring. These technologies are generally
provided to patients with long-term health condi-
tions such as diabetes.
In the United Kingdom, the announcement of the
Whole System Demonstrator pilots led to the subse-
quent award of funding to teams in three areas of Eng-
land (Kent, Newham and Cornwall) to implement
service redesign to support individuals with long-term
and complex health and social care needs. This ‘whole
systems redesign’ was designed to create multidisciplin-
ary teams in health and social services and the develop-
ment of integrated care plans to deliver care more
effectively to these patient populations. An important
part of the ‘whole systems redesign’ was the introduc-
tion of telemonitoring technology in the home to sup-
port the provision of these new services and serve as an
‘effect multiplier’ for changes in service delivery (See
Figure 1). The aim of the Whole System Demonstrator
trial is to evaluate whether telehealth for people with
long-term conditions and telecare for people with social
care needs can provide cost-effective care to improve
outcomes, maintain independence, achieve significant
gains in quality of life and reduce unnecessary acute
hospital use and costs.
Evidence for the effectiveness and cost-effectiveness of
telecare and telehealth
Several reviews of the effectiveness of telecare and tele-
health have been published both within specific disease
areas [3-5] and across different areas [6,7]. Much of the
available literature refers to pilot projects and the assess-
ment of the impact of these devices on short-term out-
comes and the majority of studies do not meet robust
evaluation standards. Very few of the studies reviewed
have assessed the longer-term or routine use of such
technologies. A systematic review of 24 trials of interac-
tive health communication applications [8] most closely
relate to what is defined here as telehealth. In the
review, telehealth had a significant positive effect on
knowledge, social support, behavioural outcomes (e.g.
calorific intake, exercise and medication taking) and
clinical outcomes (e.g. asthma symptoms, HbA1c levels
and body mass index). It was not possible to determine
whether they had an effect on emotional outcomes or
overall healthcare resource use. Another recent systema-
tic review of telecare and telehealth interventions
reported an emerging evidence base for the clinical
effectiveness of telehealth technologies aimed at vital
signs monitoring but insufficient high quality evidence
for the effectiveness of telecare applications such as
safety and security monitoring [9].
The clear potential of telehealth and telecare technol-
ogy to improve care and reduce costs combined with
the lack of rigorous evidence of actual impact means
that a randomised controlled trial is required. The
remainder of this paper will describe the protocol for
the evaluation of the Whole System Demonstrator pilots
and the methodological issues raised in the evaluation.
Methods/Design
The broad research aim is to assess the effectiveness and
cost-effectiveness of (a) telehealth in the management of
patients with long-term health conditions, and (b) tele-
care in the management of patients with social care
needs. The proposed trial is a large scale, pragmatic
health technology assessment trial, designed to rando-
mise suitably large numbers of patients and assess the
impact of a broad class of telemonitoring technologies
in the context of routine delivery of NHS care [10,11].
As with any pragmatic trial, the proposed design was a
compromise between methodological, ethical and policy
issues. The optimal assessment of the cost-effectiveness
of a new health technology is a randomised controlled
trial, and this was the initial basis for all design discus-
sions. However, subsequent discussions with sites high-
lighted the importance of designing a trial that had the
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Figure 1 Telecare and telehealth as an ‘effect modifier’ of
wider system redesign.
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support of stakeholders, and that individual randomisa-
tion of patients was unlikely to be acceptable.
To deal with these issues, the proposed trial used a
cluster randomised trial design (see Figure 2). Although
many services provided to patients (especially those with
social care needs) are delivered outside primary care,
general practices were used as the unit of allocation
because they are stable organisations involved in the
care of all patients in each site.
General practices were randomised so that eligible
patients within their populations would receive access to
one technology (i.e. either telehealth or telecare). Each
practice would thus provide intervention participants for
one technology (e.g. telehealth) and control participants
for the other technology (e.g. telecare) or vice versa.
This ensured that equity of access existed at the level of
the practice population, and that no practice was asked
to risk randomisation to a no-treatment control where
all patients would be denied access.1
Clearly, the introduction of a complex suite of tele-
monitoring technologies and the associated service
changes raised more questions than could be answered
with a conventional trial alone, so that the proposed
cluster trial was used as a structure, around which a
wider evaluative process was designed in line with
current convention about the assessment of complex
interventions [12,13]. The broad evaluation structure is
outlined in Figure 3, and the research questions listed
below.
• Theme 1: Service utilisation. Does the introduction
of telehealth or telecare result in reduction of service
utilisation and costs of care?
• Theme 2: Clinical effectiveness. Does the introduc-
tion of telehealth or telecare result in improvements
in quality of life, well being, self care, and carer
burden?
• Theme 3: Cost-effectiveness. What are the economic
consequences of introducing telehealth and telecare?
• Theme 4: Patient and professional experience.
What is the experience of service users, carers and
health and social care professionals during the intro-
duction of telehealth and telecare?
• Theme 5: Service delivery and organisation. What
organisational factors facilitate or impede the sus-
tainable adoption and integration of telehealth and
telecare?
The rest of this report will detail the protocol for the
quantitative analysis of the core trial (Themes 1-3). A
Randomisation
Group 1 practices Group 2 practices
Patients with social care 
needs receive telecare
Patients with social care 
needs receive usual care
Patients with diabetes, 
COPD and heart failure
receive usual care
Patients with diabetes, 
COPD and heart failure
receive telehealth
Comparison of telecare and 
usual care
Comparison of telehealth
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Figure 2 The basic trial design.
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summary of the related qualitative work (Themes 4 and
5) can be found in Figure 4 and 5.
Themes 1-3 were all based on the same core trial
design and involved the same population criteria and
interventions, but the samples and outcome assessments
differed. The core measure of service utilisation in
Theme 1 was use of hospital services, to support a busi-
ness care for the adoption of telemonitoring technolo-
gies in the United Kingdom. Due to the large skew in
distribution of hospital use, a large sample of patients
were required (see sample size calculation below).
Therefore, all patients who receive telecare or telehealth
in the practices involved in the evaluation were to have
routine data on health and social care service extracted
from existing data sources. This did not require the
individual patient assessments required for Themes 2
and 3. Themes 2 and 3 used a subsample of patients
who were assessed using patient reported outcome mea-
sures (PROMs) and health utilisation measures to pro-
vide a more comprehensive assessment of clinical and
cost-effectiveness. The design is shown in more detail in
Figure 6.
Data collection for Theme 1 will be based on extrac-
tion from existing operational information systems in a
variety of health and social care settings. This requires
not only the extraction of large population-based data
sets, but also a method to link data using a pseudoano-
nymised identifier which protects an individual’s identify
in accord with national guidance.
Population
(a) Patients with long-term health conditions
Three clinical conditions were included in the study:
heart failure; diabetes and COPD. In the interests of
maximising external validity in this pragmatic trial, elig-
ibility was not conferred on the basis of formal clinical
assessment of disease severity (e.g. HbA1c, FEV1 % pre-
dicted, brain natriuretic peptide test). Instead patients
were deemed eligible on the basis of either (i) their
inclusion on the relevant Quality Outcomes Framework
(QOF) register in primary care, (ii) a confirmed medical
diagnosis in primary or secondary care medical records
as indicated by GP Read Codes or ICD-10 codes, or (iii)
confirmation of disease status by a local clinician (i.e.
GP, community matron) or by their hospital consultant.
Patients were not excluded on the basis of additional
physical co-morbidities.
(b) Individuals with social care needs
Inclusion criteria were informed by the Department of
Health Fair Access to Care criteria, and included people
aged 18+ meeting one or more of the following criteria:
currently in receipt of, or considered to have a need for
night sitting; receiving 10 or more hours per week of
home care; receiving 1 or more days per week of day
care; mobility difficulties; those who have had a fall or
who are considered at high risk of falling; a live-in or
nearby carer facing difficulties carrying their current
burden of responsibilities; or cognitive impairment/con-
fusion with live-in or nearby carer.
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Interventions and comparisons
The evaluation is designed as an assessment of the value
of two types of telemonitoring technology broadly char-
acterised as telehealth and telecare. Each site has sepa-
rate agreements with technology suppliers and there is
no attempt to standardise the exact technology across
sites. The analysis plan does not propose to evaluate the
effects of individual technologies and the study is not
powered to do so.
(a) Telehealth and telecare
Telehealth participants in Cornwall and Kent received a
home monitoring system comprising a base unit (the
Tunstall RTX 3370 or the Viterion V100 respectively),
which is a small device with an LCD screen and
What are the experiences of service users, carers and health and social care professionals 
regarding the introduction and use of telehealth and telecare? 
This qualitative evaluation is intended to complement as well as provide additional evidence to 
the cluster randomised trial as recommended by the MRC Framework for evaluation of complex 
interventions [47]. The main focus is to assess the impact of telehealth and telecare packages on 
the views and experiences of patients and service users (including carers) and the interaction 
between service users, carers and professionals.  An additional focus is the professional 
perspective on the use and implementation of telecare and telehealth.   
Theme 4 draws on two conceptual frameworks in the areas of telecare and self-management for 
long-term conditions. Firstly, the normalization process model [48] has been developed from 
existing evaluation studies of telecare interventions and has focused on how technologies come 
to be adapted and used (or factors involved in their failure) in routine care. Secondly, the WISE 
(Whole System Informing Self-management Engagement) model has been developed from mixed 
methods research to investigate when patient-centred self-management is likely to be most 
effective [49]. 
Aims 
? To explore patient and carer perspectives and experiences of existing services for 
chronic disease management 
? To explore patient and carer attitudes to and engagement with telehealth and telecare 
? To examine changes in management and care arrangements associated with 
interventions including impact on caring relationships (informal as well as professional) 
and use of services and resources 
? To explore professional attitudes to and engagement with telehealth and telecare 
including perceptions of the costs and benefits and changes to working practices 
? To investigate reasons for refusal of technology and withdrawal from the trial 
Methods  
A 2-year qualitative longitudinal study is being conducted using a multi-method approach: 
? Semi-structured in-depth interviews with patients, carers and professionals at multiple 
time-points through the trial 
? Observation to document technology use within patients’ homes in the context of other 
management practices, caring relationships and interactions with professionals 
? Semi-structured in-depth interviews with patients and carers who declined to take part in 
the trial following eligibility assessment 
Sampling 
In recruiting patients and carers entering the trial, a purposeful maximum variation sampling 
strategy is being used to select people from across the different sites to include a range of long-
term conditions, ages, socioeconomic status, locale, gender and illness severity. Health and 
social care staff involved in the care of people within the trial are being recruited, ensuring a 
mixture of grades of staff with various roles across all 3 sites. An opportunistic sample of patients 
who do not enter the trial following initial eligibility assessment are also invited to be interviewed 
to discuss their views about telehealth and telecare and their past and current care.       
Figure 4 Theme 4.
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response buttons to allow navigation of symptom ques-
tions and educational messages to be transmitted to par-
ticipants, together with up to four peripheral monitoring
devices. In Newham, telehealth participants received the
Philips Motiva Personal Healthcare System comprising a
set top box that connects to a television allowing symp-
tom questions, educational videos and a graphical his-
tory of recent clinical readings to be accessed via a
What organisational factors facilitate or impede the sustainable adoption and integration of 
telehealth and telecare? 
 
Past attempts to mainstream telehealth and telecare have largely been unsuccessful, despite the 
growing evidence that it is beneficial at an individual and system level. In the longer term, its 
widespread diffusion will require not just a policy mandate but also a better understanding of the 
factors that ensure successful and sustainable local implementation. Health service innovation is 
not linear or orderly [50,51] and technological innovation requires both individual and 
organisational change [52]. Policy support may increase an organisation’s predisposition, but not 
its capacity, to adopt an innovation [53]. Research on the adoption of telemedicine [54] and 
telecare [55,56] and systematic reviews on telemedicine implementation success factors [57] 
point to the need for support from local ‘sponsors’ and coalition building across stakeholders.  
 
Aims 
 
Theme 5 is exploring the challenges in scaling up from the Whole System Demonstrator trials to 
adopt and diffuse telehealth and telecare on a mainstream basis. It is assessing the 
implementation process across the range of stakeholders involved in planning, delivering, 
operating and embedding these technologies, and highlighting the lessons learnt for improving 
the future implementation of telehealth and telecare in the UK.  
 
This study involves a qualitative analysis of organisational and contextual factors in the 
implementation of telehealth and telecare within the three sites. The emphasis is on the decisions 
taken by local stakeholders, including the equipment supply chain, and their impact on the 
implementation outcomes. The role of strategic policy and operational decisions and targets, and 
relationships between organizations and between professional groups are likely to be of particular 
importance. The impact of the boundaries on local implementation practice set by the evaluation 
itself are also likely to be of importance.    
   
Methods 
 
An in-depth, comparative, longitudinal analysis of implementation within the 3 sites, focusing both 
on processes and outcomes [58,59] is being conducted. The case study method is useful where 
the range of issues is wide, the concepts are related in complex ways [60] and context is 
important [61].   
 
Qualitative data is being collected through semi-structured interviews with representatives from 
key stakeholders involved in the sites (e.g. local social service and housing authorities, primary / 
acute care trusts, private sector equipment suppliers and installers) from ‘set-up’ to the 
‘completion’ phase . The sample has been selected purposively to include appropriate 
stakeholders and to include a range of experiences.  
 
To situate the research within the context of telehealth and telecare adoption in the UK, we are 
reviewing relevant literature and monitoring policy and organisational developments. This 
involves regular access to websites, meeting with key local and national personnel, attending 
conferences, and monitoring of new research. Findings will be used to inform policy and develop 
a conceptual framework about telehealth and telecare implementation that takes into account the 
interaction between context, mechanism and outcome.  
 
Parallel to the Whole System Demonstrator programme, we are exploring the process of 
implementation and progress made in remote care services in 6 sites that are not part of the trial. 
Studying sites that are and are not constrained by conditions in a trial will shed light upon context-
specific and generic factors influencing the implementation of these services and their likelihood 
of  sustainability in the absence of external support. Matched semi-structured interviews with 
stakeholders in 3 Whole System Demonstrator sites outside the trial (Lincolnshire, Croydon, 
Norfolk) and 3 other non-Whole System Demonstrator sites (Surrey, Durham, Sandwell) have 
been carried out. The findings from this study are helping us understand how different 
management structures and contexts impact on implementation 
Figure 5 Theme 5.
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dedicated channel, plus an equivalent range of periph-
eral monitoring devices. Sites used different protocols
for allocating peripheral devices but across all sites the
critical devices by condition were a pulse oximeter (for
COPD), a glucometer (for diabetes) and weighing scales
(for heart failure). Participants with multiple conditions
received multiple peripheral devices. Participants were
asked to take clinical readings up to 5 days per week at
the same time each day but the frequency was adjusted
according to their individual history (e.g. a participant
with diabetes and well controlled blood glucose would
be asked to take readings less frequently than one with
poorly controlled blood glucose). In Cornwall and New-
ham the base unit or set top box provided a visual and
audio reminder when readings were due. At the end of
each session data from clinical readings and symptom
questions were sent to a monitoring centre via a secure
server either automatically (in Cornwall and Newham)
or following participant authorisation (in Kent).
Across all sites, telecare participants received a Tun-
stall Lifeline Connect or Connect+ base unit and pen-
dant alarm together with any number of 27 peripheral
devices classified into four broad categories: personal
health and well-being sensors (e.g. bed/chair occupancy
sensors, enuresis sensor, epilepsy sensor, fall detector,
medication dispenser), sensory impairment aids (e.g. big
button telephone, wearable vibrating alert), safety and
security aids (e.g. bogus caller button, key safe) and
environmental monitoring sensors (e.g. carbon monox-
ide detector, heat sensor, flood detector). Peripheral tel-
ecare devices were allocated on the basis of a needs
assessment and participants with multiple needs were
allocated appropriate combinations of peripheral devices.
Telecare is primarily a passive system to monitor beha-
viour (via sensors around the home), facilitate indepen-
dent living (via aids for memory, safety and sensory
impairment) and raise alarms either automatically (via
sensors) or manually (via a personal alarm or pull cord)
in the event of an emergency. As such there was no
required behavioural regimen that telecare intervention
participants were expected to adhere to (i.e. they were
not expected to take any clinical readings or answer
symptom questions on a regular basis via the base unit
or set top box). Data from sensors and alarms were
automatically sent to a monitoring centre via a tele-
phone line.
Monitoring centres were staffed by specialist nurses
and community matrons. Incoming telehealth readings
were automatically classified using a traffic light system
of red, amber or green alerts based on relevant NICE
guidelines or on individually tailored criteria specified
by clinicians familiar with the case history. Red alerts in
telehealth usually represent an opportunity for early
intervention to prevent or minimise imminent clinical
deterioration (e.g. titration of medications in response to
a sudden weight change in heart failure may prevent
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Figure 6 Detailed study design.
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critical exacerbation of symptoms and avoid the need
for more costly and/or more risky treatments). Incoming
data from certain telecare sensors (e.g. fall detector, heat
sensor, smoke alarm) generated a red flag if outside set
parameters to indicate a potential emergency situation
requiring an immediate response. Other telecare sensors
(e.g. bed/chair occupancy sensors) generated more
ambiguous information and usually required contact
with the user to establish their status. Telehealth alerts
were typically monitored during office hours on a daily
basis (Monday to Friday), while telecare alerts were
monitored 24 hours per day, 365 days per year. Moni-
toring centre staff provided a stepped-care response to
alerts ranging from reviewing recent clinical readings
but taking no further action or requesting a repeat read-
ing (these responses are for telehealth only) through to
contacting the participant via the base unit or telephone,
visiting the participant or referring on to another health-
care professional (e.g. GP, secondary care services or
emergency services).
(b) Waiting list controls
Telehealth and telecare participants randomised to the
control arm received standard health and social care for
12-months and then, subject to re-assessment, were
offered telehealth or telecare at the end of trial.
Outcomes
Theme 1 will collect and link large, administrative data-
sets with the aim of tracking service use for (a) up to
three years pre-intervention and (b) 12 months post-
intervention. It will include an assessment of hospital
utilisation, including emergency and elective inpatient
admissions, inpatient bed day use, outpatient atten-
dances and accident and emergency visits; primary care
utilisation, including GP encounters, prescription drugs
and community matron visits; and, if possible, social
care utilisation such as the use of domiciliary and resi-
dential care. Costs will be attributed to activity using
national Payment by Results tariffs and reference costs.
Theme 2 and 3 include a comprehensive assessment
of PROMs and health utilisation measures at 3 and 12
months, including general quality of life [14-16], dis-
ease-specific quality of life (teleheath only) [17-19], psy-
chological well being [20,21], perceived acceptability of
telemonitoring devices; use of telehealth and telecare;
attitudes, self-efficacy and self-care behaviours [22-25],
clinical outcomes (for telehealth participants), social net-
works [26], illness burden [27], disability [28,29] and
health care and social services utilisation [30,31]. Carer
outcomes include carer anxiety and caregiver strain
[32,33], and carer costs include carer time spent in pro-
viding care to the participant as well as lost productivity.
The full range of assessment instruments is provided
online (Additional file 1).
Sample size calculation
(a) Sample size calculation for Theme 1
The primary outcome measure was taken as the propor-
tion admitted to hospital, with the secondary outcome
measure being number of bed days. It was thought
important to be able to detect a relative change in
admission proportion of between 15% and 20%, from a
baseline of 25% (estimated from actual site data), and a
change in bed day use of 20%, both at power of 80%
and two-sided p-value of < 0.05. Previous studies in the
older population suggested that the intra cluster correla-
tion (ICC) for admissions would be around 0.001 [34].
Sample size calculations were carried out using appro-
priate formulae [35] and suggested that a sample of
3,000 patients would allow the detection of a relative
risk reduction (RRR) of 17.5% in admission proportion
and a 20% reduction in bed days using the above cri-
teria. Given that two separate RCTs of telehealth and
telecare were being run, this means that the overall tar-
get sample size for Theme 1 was 6,000 patients.
(b) Sample size calculation for Theme 2 and 3
The sample size requirements were calculated in rela-
tion to COPD using the most plausible condition-speci-
fic health related quality of life measure: the Chronic
Respiratory Questionnaire (CRQ) and its key dimension
(the dyspnoea scale). Baseline mean scores were esti-
mated at between 2.3 and 3.3 with a standard deviation
of 1.0 [36]. Taking the minimal clinical important differ-
ence (MCID) at a conservative 0.3 [37], the effect size
(given the observed baseline SD of 1.0) would be 0.3.
Since ICC values of around 0.03 for both morbidity [38]
and health related quality of life [39] variables have been
reported, the ICC was estimated at 0.01 and 0.05. With
power of 80% and two-sided p-value of < 0.05, the
required sample size would be between 200 and 300 per
condition (i.e. an overall sample size of 900), assuming
the effect size for the health related quality of life mea-
sures is around the same level of 0.3 for the other
conditions.
Trial procedures
General practices were approached by letter inviting
them to take part in the trial. Once a practice had con-
sented, potential participants for telehealth were identi-
fied in each site using existing registers of patients with
long-term conditions in general practice. Potential parti-
cipants for telecare in each practice were identified from
databases held by social services departments.
To meet ethical obligations, patients were asked to
complete and return a ‘data sharing letter’ if they con-
sented to their data being shared with the research
team. Once this letter was received, patients received a
‘light touch’ visit from a member of the project team in
each site, where consent was taken to (a) participate in
Bower et al. BMC Health Services Research 2011, 11:184
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the main trial (Theme 1) and (b) the questionnaire study
(Themes 2 and 3).
Participants who agreed to take part in the Themes 2
and 3 were subsequently contacted by a market research
company to arrange a convenient time for the baseline
interview. At this interview, patients received informa-
tion about this part of the study and signed consent.
The baseline assessment varied by participant status (i.e.
COPD, heart failure, diabetes, telecare, carers) but each
comprised a core of standardised PROMs. The PROMs
were self-completed by the participant with the
researcher on hand to explain or clarify. Data on health
care utilisation were collected via interview. The average
total time for assisted baseline interview completion was
80 minutes.
Carers of service users in the trial were identified by
sites usually at the ‘light touch’ visit, either by the carer
expressing an interest or via snowball sampling (i.e. ask-
ing participants if they had an informal carer at the
baseline interview).
Each practice was allocated to groups via a centrally
administered minimisation algorithm. The allocation
determined the technologies available to each practice (i.
e. either telehealth or telecare) and their associated
patients. Following installation of the technologies, parti-
cipants will be followed-up for 12-months. After 12-
months, the ‘usual care’ groups were eligible to receive
the appropriate interventions.
Analysis
The overall trial essentially involves two nested trials
(one comparing telehealth with usual care, and one
comparing telecare with usual care) which will be ana-
lysed separately but using identical procedures.
Unlike other evaluations of technologies in the NHS
[40], the trial is not primarily designed to assess the
effectiveness of any particular type of telecare or tele-
health technology, and the primary analysis is at the
level of the technology type (i.e. telehealth or telecare).
There are no plans to conduct analyses of individual
technologies.
(a) Themes 1 and 3
Baseline characteristics (e.g. age; sex; ethnicity; co-mor-
bidities; risk of hospitalisation; typical hospital use) of
the patients in the intervention and usual care arms will
be compared and adjusted for where appropriate. Utili-
sation (inpatient admissions, bed day use, and cost) will
be compared between the two groups for the three
years before each patient receives the intervention, and
the 12 months afterwards using appropriate statistical
models for cluster randomised trials.
One method of analysing the results of Theme 1 will
be using a risk stratification tool, to identify individuals
at different levels of risk of future hospitalisation. Two
such tools will be used, the Patients At Risk of Rehospi-
talisation (PARR) model and the Combined Predictive
Model.2 Both of these models are in use in the NHS to
case-find patients for admission-avoidance programmes.
The aim will be to understand which patients saw great-
est changes in service use from the addition of tele-
health or telecare, according to standard metrics used
routinely to target services in parts of the NHS.
Data on health, social care and other support service
use for participants will be collected using the CSRI
[30]. Unit costs will be attached to service use data to
calculate a total cost per patient at baseline, 3 months
and 12 month follow up. Costs will be calculated on the
basis of the costs incurred in the 3 months prior to the
3 data collection points. Service use and associated costs
for participants in both trial arms will be reported under
sub-categories such as use of acute hospital services and
community social services. All cost categories will be
allocated to a perspective (whether NHS, Local author-
ity, NHS and Local authority, or public sector). The
costs of the intervention will be calculated specifically
for this study from data provided by the sites and those
costs attached to participants receiving the intervention
in the telehealth and telecare groups. Point estimates of
the costs for the control and intervention groups in
each trial arm will be derived from univariate and multi-
variate analyses of costs from all 4 perspectives.
The effectiveness of the telehealth and telecare pro-
grammes will be compared using a common unit of out-
come measurement, the QALY, to be constructed from
the EQ-5D health state classification [16] scored using
established algorithms (York Tariff) [41]. QALY scores
will be calculated for the baseline, 3 month and 12
month follow-up points. In addition, scores from a
broader measure of quality of life intended for health
and social care evaluations, the ICECAP [14], will be
examined. ICECAP scores at each time point will be
presented for all three time points. Incremental cost
effectiveness ratios (ICER) will be calculated at the 3
month and 12 month follow up points for both trial
arms. The ICER will be defined as the difference in
mean costs incurred by the treatment groups in each
arm over the previous 3 month period, divided by the
difference in mean QALY gain between those treatment
groups. A cost-effectiveness acceptability curve (CEAC)
will be produced, based on the results of a model of net
monetary benefit for clustered data. The CEAC allows
the decision-maker to see what is the likelihood of tele-
health and telecare being cost-effective at different
monetary values of increments of improvement in the
chosen outcome.
(b) Theme 2
Clinical effectiveness (quality of life, well-being, self-care,
and carer burden) at 3 and 12 months will be compared
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between the groups, taking into account scores at base-
line, and adjusting for potential confounders where
appropriate, using statistical models suitable for cluster
randomised trials.
The telehealth trial involves three separate clinical
populations, and we will assess the differential impact of
telehealth in these different clinical populations using a
pre-specified subgroup analysis across conditions
(including a group with co-morbidities).
Discussion
The proposed study is an ambitious project that is
designed to provide a pragmatic yet rigorous assessment
of the benefits of (a) telehealth in the management of
patients with long-term health conditions, and (b) tele-
care in the management of patients with social care
needs. Figure 7 shows the CONSORT diagram for the
recruitment to the trial which shows that 97% of the
patient sample size target has been achieved.
Advantages and disadvantages of the proposed design
Adoption of the cluster design means that individual
patients are not randomised to technology or usual care.
This overcomes concerns raised by the participating
sites, who felt that individual randomisation was unlikely
to be acceptable to patients or professionals: in the
adopted design, all general practices will have immediate
access to the roll-out of telemonitoring equipment for at
least some of their patients. The design thus overcomes
concerns about resentful demoralisation among prac-
tices [42] if some practices had been randomised to
usual care for all their patients, especially as all partici-
pants are assessed for the technology after 12 months.
The current study is a cluster randomised design, using
general practices as the unit of randomisation. However,
the present design is an ‘individual cluster’ design [43].
This means that a cluster randomised design has been
adopted for various reasons, but the intervention is still
delivered to individual patients. This is unlike a ‘cluster
cluster’ design, where patients in the cluster cannot
refuse the intervention (e.g. a water fluoridation trial).
Clearly, the planned analysis by type of technology
(telehealth and telecare) ignores differences within tech-
nologies. The study has not been powered to explore
the effects of individual technologies, but combining dif-
ferent technologies into the primary analysis will lead to
debates about their comparability [44]. The qualitative
data from Theme 4 may be a useful source of data on
variation among users and professionals in their experi-
ence of different technologies.
It is important to note that all practices taking part in
the evaluation are part of the Whole System Demonstra-
tor pilots, and thus all practices and patients are poten-
tially benefiting from the wider service redesign that is
ongoing in these sites. Therefore, the study is assessing
the added value of telehealth and telecare technologies
over and above the effects of this wider service redesign,
and not the benefits of whole systems redesign versus
conventional care (see Figure 1). There will therefore be
issues concerning the generalisability of the results,
because the sites which are part of the Whole System
Demonstrator pilots have been specifically chosen for
their innovations in these areas of care.
The themes address related issues using a range of
methods. For example, Theme 1 exploits large, existing
sources of administrative data on service use while
Theme 3 collects self-reported data from patients. Sev-
eral studies have compared health care utilization as
described in administrative and self-reported data
[45,46]. These have typically found significant differ-
ences, especially for people with high levels of use, older
people, and for people with poor health status. The trial
is also novel in the ways that it exploits data linkage
across a range of operational data sets. The advantages
of this approach are that it allows the team to access
large volumes of computerised data relatively cheaply.
This enables analyses of much larger groups but also
includes historical data which can be used for risk
adjustment and sub-group analyses. The disadvantages
are that the data in administrative systems may be of
poor quality and it may not capture the most important
variables. The combination of administrative data
(Theme 1), and directly recorded patient events (Theme
3) provide an opportunity to test whether data problems
create different results.
The potential of telehealth and telecare technology to
improve care and reduce costs is limited by a lack of
rigorous evidence of actual impact. If telehealth and tel-
ecare technology proves cost-effective in our trial, it will
provide additional options for health services worldwide
to deliver care for populations with high levels of need.
Endnotes
1 Originally a different design was planned. The funder
wished to know the effects of the telehealth and telecare
Randomisation
Intervention Control
Telehealth (n=1605)
Telecare (n=1276)
Telehealth (n=1625)
Telecare (n=1324)
Figure 7 CONSORT diagrams (baseline data only).
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interventions, used alone and in combination for
patients with health conditions and social care needs.
The initial design was a complex factorial to allow esti-
mation of the effects of (a) the individual technologies
on patients with (i) long-term conditions (ii) social care
needs and (b) the effects of the combination of technol-
ogies on patients with both long-term conditions and
social care needs (see Additional file 2). In practice it
was found that the majority of patients were exposed to
one technology alone, and therefore the simpler design
was eventually adopted.
2http://www.kingsfund.org.uk/current_projects/
predicting_and_reducing_readmission_to_hospital/
Additional material
Additional file 1: Assessment instruments. List of assessment
instruments used in Theme 2 and 3.
Additional file 2: Original trial design. A figure showing the original
design of the trial.
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